A Study of Guselkumab Given After Ustekinumab in Participants With Moderate to Severe Psoriasis in Routine Clinical Practice

Sponsor
Janssen-Cilag Kft.
Study ID
NCT07746583
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Study Details

The main purpose of this study is to describe how well Guselkumab works after switching from Ustekinumab in participants with moderate to severe psoriasis in a routine clinical setting. A long-term skin disease that causes red, scaly and sometimes painful, itchy patches on the skin.

Key Dates

First listed
Aug 5, 2026
Start date
Sep 15, 2026
Status verified
Aug 2026
Primary completion
Jan 30, 2029
Completion
Mar 15, 2029

Study Design

Enrollment
100 participants (estimated)

Arms

  • Arm: Moderate to Severe Psoriasis: Guselkumab Switching From Ustekinumab
    Participants with moderate-to-severe psoriasis who are candidates for systemic treatment (according to the guselkumab label) and who are medically indicated to switch from Ustekinumab or its biosimilar to receive Guselkumab in routine clinical practice will be enrolled. No drug will be provided as a part of this study. Only data available from routine clinical practice will be collected.

Primary Outcome Measure

Percentage of Participants Achieving Absolute Psoriasis Area Severity Index (aPASI) <=3 at Week 20 Following Switch from Ustekinumab to Guselkumab [ Time Frame: At Week 20 ]

Central Contacts

Find similar trials

Nationwide
Psoriasis trialsDermatology trialsRheumatology trialsAutoimmune disease trials

Related Studies